Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • wilderguide wilderguide Nov 13, 2011 5:07 AM Flag

    Low dose data

    Good job, Ernie. I noticed that the AE5 in the DTC trial had received prior mediastinal XRT. Mightn't this alone account for a higher statistical potential for mortality? Doesn't this sort of requalify or recategorize this particular AE?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • <<I noticed that the AE5 in the DTC trial had received prior mediastinal XRT. Mightn't this alone account for a higher statistical potential for mortality? Doesn't this sort of requalify or recategorize this particular AE?>>

      It certainly should be looked at as a mitigating factor, but the VEGF inhibitors as a class have a history of causing fistulae and Cabo has this history also. Although obviously in pretty tough shape, this AE5 was at least ECOG 1 at trial entry, so it is hard to argue that the assignment as a treatment induced mortality is not justified.

    • Another study; Again Cabo hits it out of ballpark.

 
EXEL
7.80+0.02(+0.26%)Jun 29 4:00 PMEDT